ERS Genomics Limited ('ERS Genomics'), the CRISPR licensing company, today announced that it has signed a non-exclusive ...

A 2026 review finds that phages show biological plausibility and limited preclinical activity against multidrug-resistant ...

Called Cas12a2, the CRISPR system had some distinctive properties. Rather than editing cells’ DNA when prompted by a guide RNA, as CRISPR-Cas9 does, Cas12a2 indiscriminately shreds it, ultimately ...

A 2026 review summarizes advances in CRISPR-Cas9 precision, delivery and primary-cell engineering for genetic diseases and ...

Isaacson argues that who patents, regulates, and profits from gene editing now matters as much as the science, because rewriting human heredity is no longer theoretical.